Tissue Regenix Group PLC's (AIM:TRX) first-half results highlighted the benefits and efficiencies being derived from investment and reorganisation in manufacturing capacity with the first underlying EBITDA-positive reporting period, says research house Hardman.
"With further strong growth forecast in 2H’23, TRX is on the cusp of achieving profitability. Phase 2 of its capacity expansion programme is expected to be completed in 2025."
TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse).